4 results
Primary Objective:To induce clinical response (CDAI decrease from baseline * 100 points) and/or remission(CDAI <150) following 12 weeks of treatment with one of two active doses ofGSK1605786A for qualification of subjects for enrolment into a…
Primary: Safety and tolerability. Secondary: Effectiveness, quality of life, healthcare resource utilisation, work productivity.
In this study we will investigate how safe specific doses of the compound paltusotine are and how well these are tolerated when they are used by healthy participants.We also investigate how much of the compound is broken down and absorbed in the…
Primary Objective- To evaluate immunogenicity of N9-GP (nonacog beta pegol)Secondary Objectives- To evaluate safety of N9-GP (nonacog beta pegol)- To evaluate efficacy of N9-GP (nonacog beta pegol) * in long-term prophylaxis treatment * in the…